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Abstract
Case reports suggest that solvents are associated with various connective tissue diseases
(systemic sclerosis, scleroderma, undifferentiated connective tissue disease, systemic lupus
erythematosis, and rheumatoid arthritis), particularly systemic sclerosis. A small number of
epidemiological studies have shown statistically significant but weak associations between
solvent exposure, systemic sclerosis, and undifferentiated connective tissue disease.
However, the interpretation of these positive findings is tempered by a lack of replication, an
inability to specify which solvents convey risk, and an absence of increasing risk with
increasing exposure. Existing studies, on aggregate, do not show conclusively that solvents
(either as a group of chemicals or individual chemicals) are causally associated with any
connective tissue disease. Further investigations should be carried out to replicate the
positive existing findings and to specify the solvents and circumstances of exposure that
carry risk.
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Introduction
Since the first case reports of systemic sclerosis (SSc)
associated with solvent use in 1957 [1,2] dozens of cases
have been reported, and recently scientific studies of the
associations between solvent exposure and connective
tissue diseases have been published. This paper reviews
the epidemiological evidence regarding the associations
of solvents with SSc, scleroderma, undifferentiated con-
nective tissue disease (UCTD), systemic lupus erythe-
matosus (SLE), and rheumatoid arthritis.
The precise diagnosis of a number of the connective
tissue diseases may be difficult to specify for a number of
reasons, all of which pose difficulties for the conduct of
epidemiological studies. Clinical features including Ray-
naud’s phenomenon, polyarthritis, interstitial lung disease,
pleuritis, pericarditis, and vasculitis can be seen in
rheumatoid arthritis, SLE, SSc, polymyositis, dermato-
myositis, and Sjögren’s syndrome. There is also overlap in
the serology associated with these disorders, including
antinuclear antibodies, rheumatoid factors, and immuno-
globulin G autoantibodies. Signs and symptoms may
evolve over a period of years, making it difficult to specify
a date of disease onset. It is also possible to have more
than one systemic rheumatic disease concurrently. Partial
overlap of features of two or more diseases has beenArthritis Research    Vol 2 No 1 Garabrant and Dumas
estimated to occur in 15–25% of tertiary referrals.
Because of these issues, the identification of cases and
the determination of the date of onset of disease for each
case often require a detailed review of clinical records and
the application of strict criteria in order to ensure the accu-
racy of data used in epidemiological studies.
Principles of epidemiological study design
The strengths and inherent limitations of each of the two
basic epidemiological study types must be considered in
order to assess the validity of the epidemiological litera-
ture. Cohort studies typically focus on two or more groups
of people who are free of disease (in this case, the con-
nective tissue disease under study) and who differ with
regard to exposure (solvents). The groups are followed
over time and the disease incidence rates for the exposure
groups are calculated and compared. Strengths of the
cohort design are that exposures are defined and expo-
sure records are commonly maintained before the initiation
of the study, and there is relative confidence that the expo-
sure information is reliable. These are critical issues in
establishing an association between exposure and
disease outcome. Cohort studies typically do not rely on
the recollections of individuals’ past exposures, which can
introduce substantial errors (including both random errors
and bias). Even when written records of exposure are
available, difficulties can arise in identifying the chemical
composition of the exposure and in quantifying the expo-
sure in terms of intensity, frequency, and duration.
Reliance on biomarkers in future studies might partly over-
come these limitations.
Case–control studies, when correctly designed, are con-
ducted within the source population from which cases are
identified. The exposure status of the cases is usually
determined by their recollections of past exposures
(although written exposure records are used if they exist).
Control individuals are selected from the same source
population for the purpose of estimating the distribution of
exposures in the population from which the cases arose.
In order to achieve this, control individuals must be
selected independently of their exposure status, and their
exposure status must be established in the same manner
as for the cases. One of the principal limitations of
case–control studies pertains to the limited accuracy of
individuals’ recollections regarding distant past exposures.
This is especially problematic when individuals are asked
to recall past chemical exposures, because they might not
know the names of the chemicals, they might be unable to
differentiate between meaningful and trivial exposures, and
they might be unaware of exposures that they do not smell
or touch. In addition, cases may be biased toward report-
ing exposures that they think may have contributed to their
illness, whereas control individuals have no comparable
motivation. This bias may create an apparent association
between exposure and disease. These issues are of
concern in many of the published studies on solvents and
connective tissue diseases, and they affect the reliability of
the findings of those studies. Investigators often take
steps to increase the reliability of exposure information.
These steps include inferring exposures based on the indi-
viduals’ descriptions of jobs, hobbies, and chemical use;
and having the individuals’ recollections reviewed by an
expert to judge the reliability of the information based on
the expert’s knowledge of typical exposure levels in
various tasks and industrial processes.
Biomarkers of exposure are available for a number of the
common solvents that have been associated with connec-
tive tissue diseases. These include measures of urinary
phenol excretion (benzene exposure), urinary hippuric acid
excretion (toluene exposure), urinary methylhippuric acid
(xylene exposure), urinary trichloroethanol and trichloro-
acetic acid excretion (trichloroethylene and 1,1,1-trichloro-
ethane exposure), and urinary tetrachloroethylene and
trichloroacetic acid excretion [tetrachloroethylene (per-
chloroethylene) exposure]. All of these biomarkers must
be measured during exposure or within 24 h of the end of
exposure in order to be meaningful. This requirement limits
their utility in epidemiological studies of connective tissue
disease in which the onset of the disease is rarely in a
close temporal relationship with solvent exposure. Historic
databases of solvent biomarkers would be of great value
to epidemiological studies, but few exist and none have
yet been used in the published epidemiological studies.
Nonetheless, biomarkers potentially offer great advan-
tages in the assessment of individual exposures if they are
available during the period of exposure for individuals
whose connective tissue disease risks are subsequently
investigated.
Case reports form much of the literature on solvents and
connective tissue disease, and these reports should not
be confused with case–control studies. Case reports are
descriptions of patients who have the disease of interest
and who have had exposure to various factors (such as
solvents) that the author believes are sufficiently unusual
that they merit a report. These reports play the important
role of suggesting new hypotheses and associations that
may deserve further scientific inquiry. Case reports often
provide no evidence that the reported associations are
causal. This is because the authors have no systematic
knowledge of whether the cases they have seen are more
likely to have been exposed than are people without the
disease, or whether the cases they have seen represent a
biased sample of the source population. When case
reports provide evidence of an appropriate temporal asso-
ciation of the exposure with the syndrome, lack of alterna-
tive causes, positive dechallenge and positive rechallenge,
dose response, and specificity of exposure and response,
they can support a causal interpretation. In the absence of
such rigorous evidence, however, these reports should behttp://arthritis-research.com/content/2/1/005
viewed as providing new ideas that deserve investigation,
but not as providing any scientific evidence of causal
associations.
Common solvents and their uses
The determination of the solvents to which an individual
has been exposed is critical to the reliability of epidemio-
logical studies. It is often difficult to infer correctly the
exact agent, not only because of the limits of the individu-
al’s knowledge, but also because the common uses for
solvents often do not require a specific chemical, but
rather only require chemical properties that can be satis-
fied by a number of chemicals or mixtures. Although
numerous chemicals have solvating properties, only
certain chemicals are thought of as solvents because of
their widespread use for this purpose. Solvents that mix
freely with water are polar (ketones and alcohols, for
example). The solvents most often reported to be associ-
ated with connective tissue disease are nonpolar, such as
petroleum distillates, trichloroethylene, and perchloroethyl-
ene. Some solvents are pure chemical compounds (ie
toluene, perchloroethylene etc). On the other hand, many
applications do not require high purity chemicals, and
therefore less expensive mixtures are commonly used,
such as paint thinner (a petroleum distillate with a range of
boiling points). Varnish maker’s and painter’s naphtha is a
mixture of paraffins, cycloparaffins, olefins, and aromatic
hydrocarbons with a boiling point range of 100–160°C
[3]. Stoddard solvent (mineral spirits) is a moderately flam-
mable mixture with a higher boiling point range of
149–205°C [4]. The term ‘paint thinner’ almost invariably
refers to petroleum distillates that do not contain chlori-
nated solvents. In addition, many solvent products are
named by their intended use rather than by chemical
content, and products having the same common name
may contain different ingredients. Paint removers are typi-
cally mixtures of solvents with additional ingredients such
as alkali (which dissolve polymerized paint resins and
waxes). Some contain chlorinated aliphatic solvents such
as methylene chloride, whereas many do not.
Solvent exposure levels in various tasks and
industry
One of the major limitations of the existing epidemiological
studies is the lack of quantitative exposure information on
the study subjects. None of the published studies reviewed
below is based on measurements of solvent exposures of
the study participants, and most are based on crude quali-
Table 1
Typical uses, upper range of reported exposure levels, and recommended exposure limits for solvents reported to be associated
with connective tissue diseases
Exposure levels ACGIH TLV: 
Solvent Typical industrial uses (mg/m3) 8 h TWA (mg/m3)
Benzene Petroleum refining product; a component of gasoline [83] 0.1–27.2 1.6
Toluene Tire vulcanization 5.66 188
Leather finishing 735
Hospital laboratory 47.5
General manufacturing [84] 452
Xylene Hospital laboratory 1700 434
General manufacturing [84] 61
Trichloroethane Nonflammable cold cleaning solvent; used alone or blended [4] Not typically 1910
used in
consumer products
Trichloroethylene Nonflammable liquid that dissolves fats, greases, tars, and waxes; 269
used for cold cleaning [4].
Degreasing [85] 4833
Also used in typographic correction fluids [86]
Perchloroethylene Nonflammable liquid used in cold cleaning where slow 170
evaporation is desired [4]
Degreasing 12204
Dry cleaning [85] 3899
VM & P naphtha Paint thinner with a boiling point range of 100–160°C [3] 1370
Mineral spirits Moderate flammability solvent with a boiling point range 525
(Stoddard solvent) of 149–205°C; dissolves oil and grease [4]
Commonly used in dry cleaning and as a paint thinner
ACGIH, American Conference of Governmental Industrial Hygienists; TLV, threshold limit value; TWA, time weighted average; VM & P, varnish
maker’s and painter’s.tative estimates of whether exposure did or did not exist in
the distant past. In putting these studies into context, it is
useful to review the uses and typical industrial exposure
levels of various solvents (Table 1). Measurements of
industrial exposure to solvents vary widely depending upon
the type of use or particular facility investigated. Exposures
in household settings and hobby uses such as cleaning,
furniture restoration, and crafts are even more variable
because of the variations in ventilation, the absence of
training, the lack of legal regulations, and the idiosyncratic
nature of people’s work habits in the home.
The exposure levels given in Table 1 represent the upper
end of the typical exposures for these agents in various
settings, rather than the entire range. Because exposure
measurements can range from low as the limit of detec-
tion, the actual exposure levels in any setting may range
from negligible to the levels contained in Table 1. Some of
the reported high exposures are from historic reports, and
such exposures would be unlikely to occur at the present
time in regulated settings. Table 1 also contains the Ameri-
can Conference of Governmental Industrial Hygienists
recommended maximum exposure level over a full 8-h
work day for each solvent. These recommendations, which
are referred to as threshold limit values for 8-h time
weighted average exposures, are airborne concentrations
that are believed to be without appreciable health conse-
quences for almost all adults. That these limits are not
exceeded is not enforced by any regulatory authority in
any country, but they are widely regarded as reasonably
safe in many nations.
Systemic sclerosis and scleroderma
SSc is a rare disease that is estimated to affect between 2
and 10 people/million each year in the Western world [5].
Females are more commonly affected than males, with a
female : male ratio of between 3:1 and 8:1, which is
more marked in early adulthood and which diminishes later
in life [5]. Although reasons for the female predominance
are unknown, the higher prevalence of solvent exposure
among males than among females suggests that solvent
exposure is unlikely to explain a large proportion of female
cases. There is no urban–rural difference in incidence [6].
The incidence is slightly higher among blacks than among
whites in the USA [7]. Traditionally, it was thought that
genetic factors were not major causes of scleroderma.
This belief was based on studies of twins that did not
show findings that are inconsistent with chance. Also,
early immunogenetic studies of human leukocyte antigen
(HLA) [5] showed either weak or inconsistent associations
that were unable to explain risk. Several recent investiga-
tions suggest that genetic factors play a complex role in
scleroderma, however.
Englert et al [8] investigated familial risk estimation in a ret-
rospective cohort study involving 715 SSc patients and
371 randomly recruited age-matched and sex-matched con-
trols in Australia. They found that the relative risk for SSc in
a subsequent first-degree relative was in excess of 11-fold,
compared with risk in an initial first-degree family member.
The Choctaw Native Americans in southeastern Oklahoma
have the highest prevalence of scleroderma or systemic
sclerosis yet found (469/100000). Tan et al [9] studied
25 cases and 77 controls within this population. They
found that a particular genetic marker [a 2cM haplotype
on chromosome 15q that contains fibrillin 1 gene (FBN1)]
was significantly more frequent in SSc cases than in con-
trols. In a subsequent study that involved 18 cases and 76
controls within this same population, Tan et al [10] found
another haplotype (an extended HLA-DR2 that includes
the class I and III regions) that was also significantly asso-
ciated with scleroderma.
Fanning et al [11] performed genetic studies on 130 SSc
cases and 602 cadaveric controls in the UK. They specu-
lated on the possibility of three distinct disease types,
based on their finding of three distinct and mutually exclu-
sive antinuclear antibody types that were each correlated
with different alleles and disease characteristics.
Further studies of HLA class II genes were carried out by
Kuwana et al [12] on 105 unrelated Japanese SSc patients
and 104 race-matched healthy control individuals. Those
authors concluded that particular alleles do not significantly
affect the likelihood of developing disease, but they do affect
the type of autoantibody produced if disease does develop.
The particular type of autoantibody then controls the clinical
presentation of the disease. For example, HLA class II alleles
DRB1*0101-DQB1*0501-DPB1*0402 result in expression
of anticentromere antibody and this results, clinically, in a
limited cutaneous variant of the disease.
The role of genetic factors in the development of SSc
creates potential complications in terms of epidemiological
study design assumptions, if certain genotypes have differ-
ent disease susceptibilities. Frank et al [13] performed a
retrospective study with 30 SSc cases exposed to
quartz/metal dust, 50 idiopathic cases of SSc, and 314
healthy control individuals, in Germany. Genetic studies
indicated that the HLA-DRB1*0301 (DR3) haplotype was
very frequent in the quartz/metal dust antitopoisomerase-
responding group (ie a susceptibility haplotype), whereas
in the idiopathic group this haplotype was infrequent in the
antitopoisomerase-responding group (ie a neutral or pro-
tective haplotype). Significant confounding effects might
have been present in this particular study design, however,
because the quartz/metal exposed group consisted of
uranium miners (29 out of 30 were men) and the idiopathic
group consisted mainly of women (46 out of 50). Future
genetically oriented epidemiological studies will be helpful
in answering the issues posed by these studies.
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ing scrutiny in recent years, in part because crystalline
silica (silicon dioxide) [14–20] is an established cause of
SSc and vinyl chloride monomer [21,22] causes a syn-
drome that has many features in common with SSc [23].
There have been a number of reviews of the literature on
chemicals and SSc, which contain detailed lists of the
agents reported to be associated with SSc. In 1996 Silman
and Hochberg [24] reviewed the evidence on environmental
causes of scleroderma. They listed many chemical com-
pounds that have been linked to scleroderma in case
reports [benzene, bis(4-amino-3methyl-cyclohexyl) methane,
dieseline, dimethylbutylphenyldiamine, heptane, metaphenyl-
enediamine, toluene, toluidene, trichloroethane, trichloro-
ethylene, vinyl chloride, xylene, and xylidene]. Haustein and
Herrmann [25] reported that trichloroethylene, perchloro-
ethylene, hexachloroethane, hexachlorobenzene, benzene,
toluene, naphtha, n-hexane, and diesel oil have been linked
to scleroderma. Haustein and Ziegler [23] reported and
reviewed cases of scleroderma in patients exposed to
trichloroethylene, benzene, toluene, xylene dieseline, and an
amine component of epoxy resins [bis(4-amino-3-methylcy-
clohexyl)methane]. The postulated mechanisms by which
trichloroethylene and related compounds may cause SSc
include metabolism to epoxy compounds that subsequently
bind to proteins, creating autoantigens [24] and solvent-
induced [25] endothelial cell injury that leads to microvascu-
lar abnormalities and ultimately target organ fibrosis.
Case reports
Case reports concerning the suspected link between scle-
roderma and solvents have been reported for more than
30 years. Walder [26] reported seven cases in 1965
(linked to toluene, benzene, and white spirits), and five
cases in 1981 (linked to toluene, xylene, white spirits, and
dieselene). Zachariae et al [27] reported that 13 out of 28
men with SSc reported prior exposure to organic solvents.
Garcia-Zamalloa et al [28] reported a case of SSc follow-
ing 23 years of employment in a tire factory where there
was potential for exposure to toluene, heptane, dimethyl-
butylphenyldiamine, and octaphenol formaldehyde. Czirjak
et al [29] reported a case in a woman who was chronically
exposed specifically to trichloroethylene in the workplace.
Following 3 years of exposure, she developed Raynaud’s
phenomenon, acrosclerosis, and joint symptoms. This pro-
gressed to esophageal involvement after 7 years of expo-
sure, and ultimately to cardiac and renal involvement after
13 years. One case study by Lockey et al [30] suggested
that scleroderma can occur as the result of a single acute
exposure. Those investigators described the case of a 47-
year-old woman who received significant dermal exposure
to trichloroethylene over a period of 2.5h. During the next
few days she developed fatigue and a pruritic macular
rash over the exposed areas. Four months later, she devel-
oped symptoms of fatigue, myalgias, arthralgias, dyesthe-
sias of the hands and feet, and some skin tightness in her
hands. Over the course of five more months, she devel-
oped increased skin tightness, and systemic involvement
including her esophagus, kidneys, and lungs. Ten months
after the initial exposure she died as a result of pulmonary
failure. Autopsy revealed SSc affecting the esophagus,
lungs, skin, and kidneys. Three cases were reported by
Flindt-Hansen and Isager [31], two of which were thought
to be the result of trichloroethylene and trichloroethane
exposure during metal cleaning. Those individuals had
been exposed for 12 and 14 years. The third case
involved trichloroethylene exposure alone, however; that
patient was exposed for only 4 years. Chloroform expo-
sure (in a man repairing carburetors for 13 years) has
been implicated as a cause for SSc by Tibon-Fisher [32].
After 15 years of regular hand washing with trichloro-
ethane, xylene, trimethylbenzene, and naphthalene in a
foundry, a 41-year-old man developed SSc. Czirjak and
Szegedi [33] reported that 17 female patients from a pop-
ulation of 61 patients with SSc had been exposed to
chemicals. The development of SSc in a 39-year-old man
who used trichloroethylene as a degreaser has been
reported [34].
Cases of localized skin scleroderma (morphea) have also
been reported. A 26-year-old woman occupationally
exposed to a variety of solvent vapors (trichloroethylene,
tetrachloroethylene, acetone, benzene, isopropyl alcohol,
dimethyl phthalate, methoxyethanol, polyethylene glycol,
polyvinyl alcohol, polyvinyl acetate, xylene, and phenol) for
1 year developed morphea on her arms and ankles [35].
This resolved after 1 year of treatment. A 45-year-old man
exposed to 10–25 parts per million perchloroethylene in
the workplace for a period of 1 year developed morphea
[36]. Yamakage and Ishikawa [37] reported seven cases
of morphea in which the potential for occupational expo-
sure to a variety of solvents might have been present.
The large collection of case studies (of which there are many
more reported in the literature than are reviewed here) raises
hypotheses that SSc and scleroderma may be caused by
any of a large number of chemically unrelated agents under
circumstances of exposure that may be brief, prolonged, fre-
quent, or infrequent, and may involve skin contact or inhala-
tion, or both. It is unlikely that all of these observations are
correct. In order to determine which of them may be correct,
epidemiological studies have been undertaken to determine
which solvents and which circumstances of exposure are
associated with SSc and scleroderma.
Epidemiological studies
There have been a number of case–control studies that
have examined the association between various solvents
and SSc [14,38–42]. Czirjak et al [42] studied 61
patients with SSc and 61 age-matched and sex-matched
referents. The cases were derived from clinical practices
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randomly selected from a single Hungarian village. It does
not appear that the source population from which the
cases arose was the same as that from which the con-
trols were selected. This raises serious concern about the
validity of any comparison between the cases and con-
trols. The authors reported the frequency of solvent expo-
sures (benzene, petroleum distillates, isopropanol, ethyl
acetate, turpentine, and trichloroethylene) among the
cases, but not among the controls. As a result, this paper
provides no information on whether solvents are associ-
ated with SSc.
Bovenzi  et al [14,41] reported a case–control study in
Trento, Italy, in which 21 cases and 42 control individuals
(matched for sex and age) were identified from hospital
records. A statistically significant association was found
between solvents and SSc [odds ratio (OR) 9.28, 95%
confidence interval (CI) 1.08–243.8] on the basis of four
exposed cases and one exposed control individual. Three
of the four exposed cases were men. The solvents to
which the individuals had been exposed were not identi-
fied. This study suggests that solvent exposures are asso-
ciated with SSc in men, but it gives no information on
which chemicals or circumstances of exposure convey
this risk. It also provides no support for the conclusion that
solvents are associated with SSc in women.
Nietert et al [38] reported a case–control study of 178
SSc patients who were identified in rheumatology clinics
and 200 controls who had osteoarthritis, fibromyalgia,
gout, or localized musculoskeletal pain. The control indi-
viduals were not a random sample of the source popula-
tion from which the cases were selected. Subjects were
interviewed regarding their past work histories and their
past use of chemicals. Each job and industry reported was
assigned an exposure score using a job exposure matrix.
Because of concern about the unreliability of self-reported
exposures, the exposures claimed by the individuals
studied were not used in the analyses. Solvents were
associated with SSc in men, but not in women. Among
men, there were two statistically significant associations:
exposure to any solvent (OR 2.9, 95% CI 1.2–7.1) and
exposure to trichloroethylene (OR 3.3, 95% CI 1.0–10.3).
Other solvents were associated with SSc in men, but not
statistically significantly (benzene exposure OR 2.4, 95%
CI 0.8–7.1; trichloroethane OR 2.7, 95% CI not given).
The authors also found that the association between sol-
vents and SSc was present only among those subjects
who tested positive for anti-Scl-70 antibody, suggesting
that solvents may bind to topoisomerase I and trigger an
autoimmune response in susceptible individuals. This
study provides support for the conclusion that solvent
exposure is associated with SSc in men (but not women),
and that trichloroethylene specifically is associated with
SSc.
Silman and Jones [39] conducted a case–control study of
male cases in the UK. Fifty-six cases were recruited from
patient registries, 41 control individuals were identified
from friends of the cases, and 56 control individuals were
recruited from among patients of general practitioners
who provided care for the cases. Each study participant
completed a mailed questionnaire that ascertained a com-
plete work history. An expert occupational hygienist, who
was blinded to disease status, reviewed the jobs and
assigned an exposure probability. In addition, individuals
were asked about exposures to specific solvents with
which they had worked extensively. There were nonsignifi-
cant associations between solvent exposure and SSc
based on general practitioner controls (OR 1.7, 95% CI
0.7–4.1) and based on friend controls (OR 2.3, 95% CI
0.9–6.2). There was no trend of increasing risk with
increasing duration of exposure in either analysis. The
authors did not identify any of the solvents to which the
subjects were exposed. This paper provides no conclusive
evidence of an association between solvents and SSc.
Goldman [40] reported on 279 patients from a rheumatol-
ogy practice in the USA. Thirty-three people with sclero-
derma were classified as cases and the remaining 246
individuals were classified as controls. The controls were
diagnosed with dermatomyositis, polymyositis, rheumatoid
arthritis, mixed connective tissue disease, and SLE. There
was no attempt to identify controls who were representa-
tive of the source population from which the cases arose.
Study subjects completed questionnaires regarding their
history of exposure to chemicals and their past occupa-
tions. There was no attempt made to blind the investiga-
tors to disease status. There was a statistically significant
association between solvent exposure and SSc (OR 5.8,
95% CI 2.5–13.4). It is unlikely that the controls are repre-
sentative of the general population from which the cases
arose, and it is possible that selection bias may have
altered the apparent association between SSc and
solvent exposure.
Garabrant  et al (manuscript submitted for publication)
reported on 666 female patients with SSc and 2227
control individuals in Ohio and Michigan in the USA. Con-
trols were drawn from the general population and were
frequency-matched with regard to sex, race, age, and geo-
graphic region. Individuals were interviewed by telephone
regarding possible occupational exposure to solvents and
whether they had handled solvents. An expert in exposure
assessment, blinded to disease status, reviewed the expo-
sure histories and assigned a probability of exposure.
There were statistically significant associations between
SSc and paint thinners and removers (OR 1.96, 95% CI
1.46–2.62) and all solvents combined (OR 1.96, 95% CI
1.54–2.49). In addition, there were nonsignificant associa-
tions between SSc and trichloroethylene (OR 1.91, 95%
CI 0.56–6.56) and xylene (OR 1.92, 95% CI 0.59–6.29).
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analyzed and showed similar associations to those based
on the expert review. This paper supports the interpreta-
tion that there is a weak association between solvent
exposure and SSc among women. It contains no informa-
tion on risk among men. Despite its large size, it did not
identify any specific solvent that conveyed risk and the
findings were significant only for the least specific solvent
products, the identity of which could not be further
defined.
Lundberg  et al [43] carried out a cohort morbidity study of
SSc, rheumatoid arthritis, and SLE in 13 counties in
Sweden. The cohort included 375035 men and 140139
women who had worked for at least 10 years in the same
occupation. Of these, 47 males and 24 females had been
treated in a hospital for SSc, 896 males and 629 females
had been treated in a hospital for rheumatoid arthritis, and
36 males and 57 females had been treated in a hospital
for SLE. Exposures were assigned using a job exposure
matrix, based on the occupations of the subjects derived
from written public records. There was a nonsignificant
association between SSc and work with aliphatic hydro-
carbons (OR 2.1, 95% CI 0.8–5.5, based on six cases).
Other types of solvent exposure, including exposure to
gasoline and organic solvents, were ascertained but not
reported by the authors (presumably indicating that there
were no significant associations). This is an important
study because it is population based and it relies entirely
on written records rather than the recall of the study sub-
jects. It indicates that there may be a weak association
between solvent exposure and SSc, but that chance
cannot be excluded as an explanation. This study must be
interpreted as providing inconclusive evidence of an asso-
ciation between SSc and solvent exposure.
There have been many cohort mortality studies of solvent-
exposed populations, including printers [44–46], dry clean-
ers [47–50], petroleum refining and gasoline workers
[51–71], and painters [72–75]. These studies do not
support the conclusion that deaths from SSc or other con-
nective tissue diseases are associated with solvent expo-
sure. It should be emphasized that mortality studies cannot
accurately address the risks of diseases that uncommonly
cause death. Insofar as SSc has appreciable mortality in
severe cases, however, the absence of increased mortality
in this large body of epidemiological evidence should appro-
priately be viewed as providing no evidence that solvent
exposure is associated with increased risk of fatal SSc.
Undifferentiated connective tissue disease
There is often overlap in the symptoms and signs of
various connective tissue disorders, and in certain cases
months or years pass before a specific syndrome
becomes apparent. Individuals who have a number of the
findings that are consistent with SSc but who do not fulfill
the diagnostic criteria for SSc are often diagnosed with
UCTD. There is concern that those who have SSc repre-
sent only a part of a broader disease entity, and that the
causes of UCTD should be studied in addition to focusing
on SSc specifically.
Case reports of atypical scleroderma and undifferentiated
connective tissue disease
Several case reports exist concerning solvent exposure
and atypical scleroderma. A 50-year-old man employed at a
chemical manufacturer for 32 years and apparently
exposed to benzene, toluene, toluidine, xylene, xylidene,
aniline compounds, and ethanolamine developed a syn-
drome that involved cold sensitivity, a restrictive lung
deficit, peripheral neuropathy, esophageal dysfunction,
labile hypertension, and monoclonal paraproteinemia, in
addition to skin changes [76]. A 19-year-old man who had
been exposed to perchloroethylene in a dry cleaning busi-
ness for 4 years developed Raynaud’s symptoms, weak-
ness, arthralgias, abnormal liver function, and diffusely
swollen and thickened skin on his hands [77]. After 10
years of exposure to small quantities of various solvents, a
44-year-old woman developed a scleroderma-like syn-
drome with cutaneous sclerosis affecting her hands, arms
and legs, as well as arthralgias, fever, and fatigue [78].
After 27 years of intermittent exposure to trichloroethylene,
a 44-year-old man developed scleroderma as well as Ray-
naud’s phenomenon, malabsorption, lymphadenopathy,
peripheral neuropathy, impotence, and gynecomastia [79].
Epidemiological studies
A large epidemiological study of 205 UCTD cases was
performed in the USA [80] as a companion study to that
of Garabrant et al (manuscript submitted for publication),
described above. The methods were identical in both
studies and the same set of population-based control indi-
viduals was used as the referent group for the UCTD
cases as was used for the SSc cases. There were statisti-
cally significant associations between SSc and paint thin-
ners and removers (OR 2.73, 95% CI 1.80–4.16); mineral
spirits, naphtha, or white spirits (OR 1.81, 95% CI
1.09–3.02); and all solvents combined (OR 2.32, 95% CI
1.61–3.34). The self-reported exposures of the individuals
were also analyzed and showed similar associations to
those based on the expert review. This study supports the
interpretation that there is a weak association between
solvent exposure and UCTD among women. It contains no
information on risk among men.
Other rheumatologic diseases
Although consideration has been given to the role of
certain hair dye amines in the development of SLE,
organic solvents have not been implicated. It has been
suggested, however, that solvents play a role in other
rheumatic diseases. Omdal et al [81] reported that nine
women in a vulcanizing department potentially exposed to
http://arthritis-research.com/content/2/1/005trichloroethylene, toluene, ethyl acetate, white spirit, meth-
ylene chloride, perchloroethylene, xylene, 1,1,1-trichloro-
ethane, and hexane complained of arthralgias and joint
swelling during exposure. The authors postulated a link
between solvent exposure and inflammatory joint disease.
The cases were not compared with any referent group and
the results cannot be interpreted as providing scientific
evidence.
The study by Lundberg et al [43] described above also
reported results for rheumatoid arthritis. Substantial use of
organic solvents was weakly associated (but statistically
significantly, nonetheless) with rheumatoid arthritis (OR
1.2, 95% CI 1.0–1.6). Gasoline, aliphatic hydrocarbons,
and limited use of organic solvents were not significantly
associated with rheumatoid arthritis, however. Lundberg et
al also reported that male spray painters and lacquer
workers were at increased risk for rheumatoid arthritis (OR
2.4, 95% CI 1.1–5.4). Interestingly, launderers and dry
cleaners were not at significantly increased risk of rheuma-
toid arthritis. Lundberg et al reported no significant associ-
ations between solvents and SLE.
Conclusion
Of the four methodologically sound studies of SSc
reviewed above [38,39,43] (Garabrant et al, manuscript
submitted), one found a statistically significant association
with solvents in men [38] and two others found no signifi-
cant association [39,43] (Table 2). Similarly, one study
found a significant association in women (Garabrant et al,
manuscript submitted) and two others found no significant
association [38,42]. Examinations of specific solvent prod-
ucts including paint thinners and removers, gasoline,
benzene, trichloroethylene, and trichloroethane in three
studies showed only two statistically significant associa-
tions [for trichloroethylene in men [38] and for paint thin-
ners and removers in women (Garabrant et al, manuscript
submitted)] neither of which was confirmed in any other
study in men or in women. These studies, on aggregate,
do not provide conclusive evidence that solvents (as a
group of chemicals) are causally associated with SSc, nor
do they provide conclusive evidence that any individual
solvent is causally associated with SSc. A very large body
of mortality studies among cohorts exposed to paints, dry
cleaning solvents, and petroleum distillates provides no
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Table 2
Summary of epidemiological studies of scleroderma and solvent exposure
Men Women
Agent/Study OR 95% CI OR 95% CI Comments on exposure assessment
Any solvent
Lundberg et al [43] NR NR JEM
Nietert et al [38] 2.9 1.2–7.1 0.6 0.2–1.9 JEM. Maximum intensity of exposure
Silman and Jones [39] 1.7 0.7–4.1 * * ER. (General practitioner controls)
Silman and Jones [39] 2.3 0.9–6.2 * * ER. (Friend controls)
Garabrant et al (manuscript submitted) * * 2.0 1.5–2.5 ER
Paint thinners and removers
Garabrant et al (manuscript submitted) * * 2.0 1.5–2.6 ER
Aliphatic hydrocarbons
Lundberg et al [43] 2.1 0.8–5.5 NR JEM. It is not clear that the authors could
differentiate aliphatic hydrocarbons from
other solvents
Gasoline
Lundberg et al [43] NR NR JEM
Garabrant et al (manuscript submitted) * * 1.3 0.7–2.6 ER
Benzene
Nietert et al [38] 2.4 0.8–7.1 1.1 0.3–3.9 JEM. Maximum intensity of exposure
Garabrant et al (manuscript submitted) * * 0.8 0.2–2.6 ER
Trichloroethylene
Nietert et al [38] 3.3 1.0–10.3 0.9 0.3–2.3 JEM. Maximum intensity of exposure
Garabrant et al (manuscript submitted) * * 1.9 0.6–6.6 ER
Trichloroethane
Nietert et al [38] 2.7 † 1.4 0.4–4.6 JEM. Maximum intensity of exposure
Garabrant et al (manuscript submitted) * * 0.9 0.3–2.8 ER
NR, not reported (presumed non-significant); ER, expert review of self-reported exposure; JEM, Exposures assigned by use of job exposure matrix
without self reported exposure; OR, odds ratio. *Not studied; †confidence interval (CI) not given.evidence that solvents are associated with fatal SSc. On
balance, it should be noted that all four of the morbidity
studies [38,39,43] (Garabrant et al, manuscript submit-
ted) provide weak evidence of an association between
solvents (as a group of chemicals) and SSc in some analy-
ses, but that chance cannot be adequately excluded as an
explanation in most. This repeated, suggestive evidence of
an association cannot be dismissed as meaningless
unless it is refuted by larger, more definitive studies. It is
not adequate to conclude that there is a causal associa-
tion between solvents and SSc at the present time,
however. Unless the associations can be found consis-
tently, specific solvents can be identified as conveying
risk, and evidence of dose–response is demonstrated, the
inconsistent, positive associations that presently exist
should be viewed as being inconclusive evidence of a
causal association.
Additional morbidity studies of SSc will be necessary to
determine whether there is a causal association with sol-
vents. Future studies either must be conducted in popula-
tions that have a higher prevalence of solvent exposure, or
they must be substantially larger than the previous studies. It
is of interest that the study by Garabrant et al (manuscript
submitted), which included 675 cases and over 2200
control individuals, had marginal power to detect twofold
increased risks for specific solvents among women, primar-
ily due to the low prevalence of exposure. The region from
which the subjects were drawn is heavily industrialized with
automobile, aerospace, pharmaceutical and chemical manu-
facturing, in which solvent exposure is common. More
precise estimates of exposure in terms of the identity of the
solvents and the intensity and frequency of exposure will be
necessary. Opportunities to conduct such studies are most
likely to be fruitful in settings in which exposures can be
documented through work records or biologic monitoring
and to which morbidity records can be linked.
A single, large epidemiological study of UCTD [80] sug-
gests that solvents are significantly associated with this
diagnostic category in women, and that paint thinners and
removers and mineral spirits are specifically associated
with UCTD. Although that study was methodologically rig-
orous, replication of the findings is necessary before this
association can be accepted as causal.
There is a single study [43] that reported an association
between rheumatoid arthritis and solvent use, but which
does not identify any specific solvent that conveys this risk.
Replication of these findings is necessary before this asso-
ciation can be accepted as causal. There is no scientific
evidence that SLE is associated with solvent exposure.
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